Trevi Therapeutics (TRVI) EBIT (2018 - 2026)
Trevi Therapeutics (TRVI) posted quarterly EBIT of -$13.0 million for Q1 2026, down 27.61% year-over-year from -$18.0 million in Q1 2025, and down 27.22% quarter-over-quarter from -$10.2 million in Q4 2025.
Powered by 
Analysis
Trevi Therapeutics (TRVI) EBIT (2018 - 2026) Analysis & Trends
Trevi Therapeutics' EBIT history runs 9 years deep, the most recent figure standing at -$13.0 million for Q1 2026.
- In Q1 2026, EBIT fell 27.61% year-over-year to -$13.0 million; the TTM figure through Mar 2026 stood at -$50.9 million (down 2.11% YoY), while the FY2025 annual figure was -$49.3 million, up 4.26% from the prior year.
- EBIT for Q1 2026 stood at -$13.0 million, down from -$10.2 million in the prior quarter.
- The five-year high for EBIT was -$6.7 million in Q4 2022, with the low at -$14.1 million in Q3 2024.
- The 5-year median for EBIT is -$10.2 million (2025), against an average of -$10.4 million.
- The sharpest annual moves came in 2022 and 2024: EBIT climbed 19.53% in 2022, then tumbled 58.54% in 2024.
- Trevi Therapeutics' EBIT stood at -$6.7 million in 2022, then plunged by 34.19% to -$8.9 million in 2023, then plunged by 37.05% to -$12.2 million in 2024, then rose by 16.52% to -$10.2 million in 2025, then fell by 27.22% to -$13.0 million in 2026.
- Business Quant data shows TRVI's EBIT at -$13.0 million in Q1 2026, -$10.2 million in Q4 2025, and -$13.9 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -815.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -505.13 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 325.05 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 231.44 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 133.12 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Trevi Therapeutics | 2.71 Bn | 2.71 Bn | - | -17.82 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -17.82 Mn |
| Mar 31, 2026 | -13.21 Mn |
| Dec 31, 2025 | -8.33 Mn |
| Sep 30, 2025 | -11.82 Mn |
| Jun 30, 2025 | -12.32 Mn |
| Mar 31, 2025 | -10.35 Mn |
| Dec 31, 2024 | -11.40 Mn |
| Sep 30, 2024 | -13.27 Mn |
| Jun 30, 2024 | -12.36 Mn |
| Mar 31, 2024 | -10.91 Mn |
| Dec 31, 2023 | -7.80 Mn |
| Sep 30, 2023 | -7.71 Mn |
| Jun 30, 2023 | -7.18 Mn |
| Mar 31, 2023 | -6.41 Mn |
| Dec 31, 2022 | -6.66 Mn |
| Sep 30, 2022 | -8.41 Mn |
| Jun 30, 2022 | -7.82 Mn |
| Mar 31, 2022 | -7.03 Mn |
| Dec 31, 2021 | -8.27 Mn |
| Sep 30, 2021 | -6.95 Mn |